Lupuzor™ ‘database lock’ confirmed for 6 April 2018

23rd March 2018 - 4:29 pm

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces that it has been informed by Simbec-Orion, the contract research organisation conducting our Lupuzor™ pivotal Phase III trial study, that ‘database lock’ is expected on 6 April 2018 with top line results announced by mid-April 2018.

Lupuzor™ is the Company’s lead programme for the potential breakthrough compound for Lupus, a life threatening autoimmune disease.

Commenting on the trial update, Tim McCarthy, Chairman, said:With the continued robust safety record of Lupuzor™ achieved over this trial, we look forward with confidence to reporting top line results in the near future.”

For more information on the trial please visit:

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Share this article